OxyVita

OxyVita is a private biotechnology company developing hemoglobin-based oxygen therapeutics and blood substitute products for emergency medicine, transfusion alternatives, and severe blood-loss settings. Its core product, OxyVita, is a polymerized stroma-free bovine hemoglobin made using the company\u2019s proprietary Zero-Link hemoglobin polymerization process, which is designed to carry oxygen while limiting some of the liabilities seen with earlier acellular hemoglobin products. The company has also described OxyVita C / OVCCC, a next-generation oxygen carrier with coagulation-support capabilities intended for hemorrhage and remote or battlefield use. Based on available public information, the company remains private and active, with programs still in preclinical development rather than human clinical trials. OxyVita\u2019s positioning is centered on trauma care, military medicine, transfusion support, and other settings where conventional blood products are hard to access or use.